By Counterforce Health Team in Pomalyst (pomalidomide) —

How to Get Pomalyst (Pomalidomide) Covered by UnitedHealthcare in Pennsylvania: Complete PA Guide and Appeals Process

Answer Box: Getting Pomalyst Covered by UnitedHealthcare in Pennsylvania

UnitedHealthcare requires prior authorization for Pomalyst (pomalidomide) with strict step therapy requirements. To get approved, you need documented failure of at least one immunomodulatory agent (like lenalidomide), proteasome inhibitor, or anti-CD38 therapy, plus complete REMS program enrollment. First step today: Have your oncologist gather your prior treatment records and start the REMS certification process. If denied, Pennsylvania's new external review program overturns about 50% of insurance denials within 45 days.

Table of Contents

  1. UnitedHealthcare's Coverage Policy for Pomalyst
  2. Medical Necessity Requirements
  3. Step Therapy Rules and Exceptions
  4. REMS Program and Safety Requirements
  5. Prior Authorization Process
  6. Appeals Process in Pennsylvania
  7. Cost-Saving Options
  8. Common Denial Reasons and Solutions
  9. FAQ

UnitedHealthcare's Coverage Policy for Pomalyst

UnitedHealthcare covers Pomalyst (pomalidomide) as a specialty tier medication requiring prior authorization across all plan types—commercial, Medicare Advantage, and Medicaid managed care plans in Pennsylvania. The drug is managed through OptumRx's specialty pharmacy network and requires strict compliance with federal REMS (Risk Evaluation and Mitigation Strategy) protocols.

Coverage at a Glance

Requirement Details Source
Prior Authorization Required for all indications UHC PA Notification
Step Therapy Must fail ≥1 agent from required classes UHC Policy
REMS Enrollment Prescriber, patient, pharmacy must be certified FDA REMS
Authorization Period 12 months initial and renewal UHC Policy
Specialty Pharmacy Required—cannot use retail pharmacy OptumRx Network

Medical Necessity Requirements

UnitedHealthcare covers Pomalyst for these FDA-approved indications:

  • Multiple myeloma (with dexamethasone) after ≥2 prior therapies including lenalidomide and a proteasome inhibitor
  • Kaposi sarcoma in HIV-positive patients after HAART failure and HIV-negative patients

Documentation Needed

Your oncologist must provide:

  • ICD-10 diagnosis code (C90.00 for multiple myeloma, C46.x for Kaposi sarcoma)
  • Treatment history showing specific prior therapies and outcomes
  • Disease staging and current performance status
  • Combination therapy plan (typically with dexamethasone for myeloma)

Step Therapy Rules and Exceptions

UnitedHealthcare's 2024 prior authorization criteria require documented failure, contraindication, or intolerance to at least one agent from any of these classes:

  1. Immunomodulatory agent (lenalidomide/Revlimid)
  2. Proteasome inhibitor (bortezomib/Velcade, carfilzomib/Kyprolis)
  3. Anti-CD38 therapy (daratumumab/Darzalex, isatuximab/Sarclisa)

Medical Exception Pathways

If you haven't tried these agents, you can still get approval by documenting:

  • Contraindications (kidney disease, neuropathy, heart conditions)
  • Previous intolerance with specific adverse events
  • Clinical rationale why alternatives aren't appropriate
Tip: For Medicare Part D plans, you can request a formulary exception with a supporting statement from your prescriber, with decisions made within 72 hours (24 hours if expedited).

REMS Program and Safety Requirements

Pomalyst has a federal REMS program due to severe birth defect risks. All three parties must be enrolled before any prescription can be filled:

For Prescribers

  • Complete PS-Pomalidomide REMS certification
  • Counsel patients on pregnancy risks and contraception
  • Obtain signed Patient-Physician Agreement Form

For Patients

  • Females of reproductive potential:
    • Negative pregnancy test before each cycle
    • Two reliable forms of contraception during treatment and 4 weeks after
    • Monthly pregnancy testing throughout treatment
  • Males with female partners:
    • Use latex/synthetic condoms during treatment and 4 weeks after
    • Required even with confirmed vasectomy

For Pharmacies

  • Must be certified in PS-Pomalidomide REMS program
  • Verify patient and prescriber enrollment before dispensing
  • Provide mandatory counseling materials

This documentation is non-negotiable for UnitedHealthcare approval.

Prior Authorization Process

Step-by-Step: Fastest Path to Approval

  1. REMS Enrollment (1-2 weeks)
    • Prescriber registers at BMS REMS Patient Safety
    • Patient completes enrollment and pregnancy prevention counseling
    • Specialty pharmacy confirms certification
  2. Gather Documentation (3-5 days)
    • Prior treatment timeline with dates, doses, outcomes
    • Laboratory results (CBC, comprehensive metabolic panel)
    • Pathology reports confirming diagnosis
    • Current imaging or disease assessment
  3. Submit PA Request (same day)
  4. UnitedHealthcare Review (3-7 business days)
    • Standard review for non-urgent cases
    • Expedited review available for urgent clinical situations

Required Clinical Information

Your prior authorization request must include:

  • Diagnosis with ICD-10 code
  • Prior therapy details: drug names, doses, duration, reason for discontinuation
  • Current disease status: staging, lab values, performance status
  • Treatment plan: dosing schedule, monitoring plan, duration
  • REMS compliance: confirmation of enrollment for all parties

Appeals Process in Pennsylvania

If UnitedHealthcare denies your Pomalyst prior authorization, Pennsylvania offers robust appeal options with a 50% success rate in the state's new external review program.

Internal Appeals (UnitedHealthcare)

Timeline: 60 calendar days from denial date

How to Appeal:

  1. Submit via UHC Provider Portal
  2. Include additional clinical evidence
  3. Request peer-to-peer review with oncology specialist
  4. For urgent cases, request expedited review (72-hour decision)

UnitedHealthcare Response: 60 calendar days (automatically forwarded to external review if upheld)

Pennsylvania External Review

New in 2024: Pennsylvania launched its own Independent External Review Program with impressive results—259 out of 517 appeals (50%) were overturned in favor of patients.

Timeline: 4 months from final internal denial to request external review

Process:

  1. Obtain Final Adverse Benefit Determination from UnitedHealthcare
  2. Submit external review request via Pennsylvania Insurance Department website
  3. Independent Review Organization (IRO) assigned within days
  4. Submit additional supporting information within 15 days
  5. Decision within 45 days (72 hours for expedited cases)

If You Win: UnitedHealthcare must provide coverage immediately, including retroactive coverage if you paid out-of-pocket.

Getting Help with Appeals

  • Pennsylvania Insurance Department Consumer Services: Free guidance on the appeals process
  • Pennsylvania Health Law Project: Free legal assistance for complex cases
  • SHIP (State Health Insurance Assistance Program): Medicare-specific appeal help

At Counterforce Health, we help patients and clinicians turn insurance denials into targeted, evidence-backed appeals. Our platform analyzes denial letters and plan policies to identify the specific denial basis, then drafts point-by-point rebuttals aligned to the plan's own rules, pulling the right clinical evidence and citations to support your case.

Cost-Saving Options

Pomalyst's retail cost averages $23,400 for a 21-capsule pack (one cycle). Several programs can reduce your out-of-pocket costs:

Manufacturer Support

  • BMS Access Support: Copay assistance, free drug programs, benefits verification
  • Patient Assistance Program: Free drug for eligible uninsured/underinsured patients
  • Copay Cards: May reduce monthly costs to $10-25 (commercial insurance only)

Foundation Grants

  • The Leukemia & Lymphoma Society: Patient aid program
  • CancerCare: Financial assistance and copay help
  • HealthWell Foundation: Grants for multiple myeloma patients

Medicare Part D Changes

Pomalyst is included in Medicare's 2025 drug price negotiation program, with new lower prices taking effect in 2027 for Part D beneficiaries.

Common Denial Reasons and Solutions

Denial Reason How to Overturn
Missing prior therapy documentation Submit detailed treatment timeline with dates, doses, outcomes, and progression notes
REMS enrollment incomplete Ensure all three parties (prescriber, patient, pharmacy) are certified and provide confirmation
Non-specialist prescriber Transfer prescription to board-certified oncologist or hematologist
Insufficient combination therapy justification Document planned dexamethasone use and dosing schedule
"Not medically necessary" Provide NCCN guideline citations, disease progression evidence, and treatment goals
From our advocates: We've seen many Pomalyst denials overturned by submitting a comprehensive timeline showing exactly when lenalidomide was tried, the specific doses used, and documented disease progression within 60 days of the last dose. This level of detail often satisfies step therapy requirements that weren't clear in the initial submission.

FAQ

How long does UnitedHealthcare prior authorization take for Pomalyst in Pennsylvania? Standard review takes 3-7 business days. Expedited review (for urgent cases) provides decisions within 72 hours. REMS enrollment adds 1-2 weeks to the overall timeline.

What if Pomalyst isn't on my UnitedHealthcare formulary? Pomalyst is typically covered as a specialty tier medication. If it's non-formulary, you can request a formulary exception with clinical justification and prior therapy documentation.

Can I get expedited appeals in Pennsylvania? Yes, both UnitedHealthcare internal appeals and Pennsylvania external reviews offer expedited processes for urgent medical situations, with decisions in 72 hours or less.

Does step therapy apply if I failed treatments outside Pennsylvania? Yes, UnitedHealthcare recognizes prior therapy failures regardless of where they occurred. Ensure you have complete medical records from all treating facilities.

What happens if I start Pomalyst while my appeal is pending? If you pay out-of-pocket during appeals, successful appeals in Pennsylvania require retroactive coverage—meaning UnitedHealthcare must reimburse your costs.

How do I know if my pharmacy is REMS-certified? Only specialty pharmacies in the OptumRx network can dispense Pomalyst. Your prescriber or BMS Access Support can help identify certified pharmacies in your area.

When to Escalate

Contact the Pennsylvania Insurance Department if:

  • UnitedHealthcare misses appeal deadlines
  • You experience procedural violations
  • Coverage is denied after winning an external review

For complex cases requiring targeted appeals strategy, platforms like Counterforce Health can help identify specific denial reasons and craft evidence-backed responses that address your plan's exact coverage criteria.

Sources & Further Reading

Disclaimer: This information is for educational purposes only and does not constitute medical or legal advice. Coverage policies may vary by plan and change over time. Always consult your healthcare provider for medical decisions and verify current coverage details with UnitedHealthcare directly. For personalized assistance with Pennsylvania insurance appeals, contact the state Insurance Department's consumer services.

Powered by Counterforce Health—AI that turns drug denials into evidence-based appeals patients and clinicians can submit today.